Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival
From the start of maintenance therapy or Best Suppotive Care(BSC) until the date of documented progressive disease or death from any cause
12 months
No
Di Zheng, MD
Principal Investigator
Shanghai Pulmonary Hospital, Shanghai, China
China:Shanghai Pulmonary Hospital
SHPH-11ZL113
NCT01336192
April 2011
April 2013
Name | Location |
---|